S Vaidya

Summary

Affiliation: University of Texas Medical Branch
Country: USA

Publications

  1. ncbi Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
    Clin Transplant 26:853-6. 2012
  2. ncbi Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555 0178, USA
    Transplantation 85:1046-50. 2008
  3. ncbi DP reactive antibody in a zero mismatch renal transplant pair
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA
    Hum Immunol 68:947-9. 2007
  4. ncbi Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA
    Transplantation 82:1606-9. 2006
  5. ncbi Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
    Transplantation 82:1524-8. 2006
  6. ncbi Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555 0178, USA
    Clin Transplant 20:461-4. 2006
  7. ncbi Management of end-stage renal disease patients with antiphospholipid antibody syndrome
    S Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0178, USA
    Transplant Proc 37:650-1. 2005
  8. ncbi Synthesis of new and memory HLA antibodies from acute and chronic rejections versus pregnancies and blood transfusions
    S Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0178, USA
    Transplant Proc 37:648-9. 2005
  9. ncbi Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA
    Transplantation 77:1046-9. 2004
  10. ncbi Role of anti-beta 2 glycoprotein 1 antibodies in ESRD patients with antiphospholipid antibody syndrome
    S Vaidya
    Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555 0178, USA
    Clin Transplant 16:362-7. 2002

Detail Information

Publications15

  1. ncbi Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
    Clin Transplant 26:853-6. 2012
    ..This study evaluates long-term allograft survival of APA as well as patients with APAS...
  2. ncbi Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555 0178, USA
    Transplantation 85:1046-50. 2008
    ..This was used to determine MESF units required for a positive T and B flow crossmatches (FLXM)...
  3. ncbi DP reactive antibody in a zero mismatch renal transplant pair
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA
    Hum Immunol 68:947-9. 2007
    ..The MM allele DPB1*0601 also carries the DE 55-56 epitope. We conclude that positive B-cell flow crossmatch was likely the result of single MM in the DP locus...
  4. ncbi Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA
    Transplantation 82:1606-9. 2006
    ....
  5. ncbi Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
    Transplantation 82:1524-8. 2006
    ..We used a solid-phase assay to identify human leukocyte antigen (HLA) Class I and II specificities in highly reactive sera, and applied this information to predict crossmatch outcome with greater than 90% accuracy...
  6. ncbi Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555 0178, USA
    Clin Transplant 20:461-4. 2006
    ..In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant...
  7. ncbi Management of end-stage renal disease patients with antiphospholipid antibody syndrome
    S Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0178, USA
    Transplant Proc 37:650-1. 2005
    ..This study describes the clinical management of these high-risk patients on anticoagulation therapy...
  8. ncbi Synthesis of new and memory HLA antibodies from acute and chronic rejections versus pregnancies and blood transfusions
    S Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0178, USA
    Transplant Proc 37:648-9. 2005
    ..This study compared HLA antibody (abs) production following acute (AR) and chronic (CR) rejection with HLA abs production following blood transfusions (TF) or pregnancies (P) among kidney and kidney pancreas transplant candidates...
  9. ncbi Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome
    Smita Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA
    Transplantation 77:1046-9. 2004
    ..This study examines the efficacy of anticoagulation therapy in this high-risk patient population...
  10. ncbi Role of anti-beta 2 glycoprotein 1 antibodies in ESRD patients with antiphospholipid antibody syndrome
    S Vaidya
    Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555 0178, USA
    Clin Transplant 16:362-7. 2002
    ..Beta 2 glycoprotein 1 (beta 2gp1), a 40-kD plasma protein is required. In this study, we have tested a hypothesis that significant portions of our ESRD patients with APAS have antibodies only to beta 2gp1...
  11. ncbi Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study
    S Vaidya
    University of Texas Medical Branch, Galveston 77555 0178, USA
    Transplantation 69:1348-52. 2000
    ..Antiphospholipid antibody syndrome (APAS) is characterized by the presence of anticardiolipin antibodies (ACA) in association with thrombotic disorders of arterial and/or venus systems, spontaneous abortion(s) or thrombocytopenia...
  12. ncbi Improved flow cytometric detection of HLA alloantibodies using pronase: potential implications in renal transplantation
    S Vaidya
    Department of Pathology, University of Texas Medical Branch, Galveston 77555-0178, USA
    Transplantation 71:422-8. 2001
    ..fied in each case. CONCLUSION: Utilization of pronase-treated lymphocytes improves both the sensitivity and specificity of the FCXM...
  13. ncbi Campath and renal transplant rejection
    Philip G Thomas
    Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA
    Clin Transplant 18:759-61. 2004
    ..However, rejection recurred resulting in graft loss and, in addition, the patient developed post-transplant lymphoma...
  14. ncbi Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation
    Philip G Thomas
    Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555 0533, USA
    Transplantation 83:1509-12. 2007
    ..Infection rates were similar. Early results of this ongoing study indicate that a tolerogenic protocol with alemtuzumab induction and tacrolimus maintenance monotherapy is safe in immunologically high-risk renal transplant patients...
  15. ncbi Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support
    Scott D Lick
    Department of Surgery, University of Texas Medical Branch, Galveston, Texas 77555, USA
    J Heart Lung Transplant 27:1036-9. 2008
    ..Expanded use of this strategy could shorten LVAD support in many sensitized patients...